4,725 Shares in Dolby Laboratories $DLB Bought by EP Wealth Advisors LLC

EP Wealth Advisors LLC purchased a new stake in Dolby Laboratories (NYSE:DLB - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,725 shares of the electronics maker's stock, valued at approximately $379,000.

A number of other hedge funds have also modified their holdings of DLB. Alpine Bank Wealth Management purchased a new stake in Dolby Laboratories in the 1st quarter valued at approximately $25,000. Cheviot Value Management LLC purchased a new stake in shares of Dolby Laboratories in the first quarter valued at $27,000. MAI Capital Management lifted its position in shares of Dolby Laboratories by 87.1% in the first quarter. MAI Capital Management now owns 348 shares of the electronics maker's stock valued at $28,000 after acquiring an additional 162 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Dolby Laboratories during the first quarter valued at $29,000. Finally, Global X Japan Co. Ltd. purchased a new stake in Dolby Laboratories during the 1st quarter worth about $51,000. 58.56% of the stock is owned by hedge funds and other institutional investors.

Dolby Laboratories Stock Performance

Dolby Laboratories stock traded down $0.63 during trading on Friday, reaching $71.48. The company had a trading volume of 337,864 shares, compared to its average volume of 440,754. Dolby Laboratories has a 12-month low of $68.24 and a 12-month high of $89.66. The stock's 50 day moving average price is $73.73 and its two-hundred day moving average price is $75.53. The firm has a market capitalization of $6.85 billion, a price-to-earnings ratio of 26.18 and a beta of 0.93.

Dolby Laboratories (NYSE:DLB - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The electronics maker reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.72 by $0.06. Dolby Laboratories had a net margin of 19.62% and a return on equity of 11.52%. The company had revenue of $315.55 million for the quarter, compared to the consensus estimate of $305.23 million. During the same quarter last year, the firm posted $0.71 earnings per share. Dolby Laboratories's revenue was up 9.2% on a year-over-year basis. Dolby Laboratories has set its FY 2025 guidance at 3.880-4.030 EPS. Q4 2025 guidance at 0.610-0.760 EPS. As a group, research analysts expect that Dolby Laboratories will post 2.94 earnings per share for the current year.

Dolby Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, August 20th. Shareholders of record on Tuesday, August 12th were given a dividend of $0.33 per share. This represents a $1.32 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend was Tuesday, August 12th. Dolby Laboratories's payout ratio is 48.35%.

Insider Transactions at Dolby Laboratories

In other news, CEO Kevin J. Yeaman sold 25,000 shares of the business's stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $72.31, for a total transaction of $1,807,750.00. Following the completion of the sale, the chief executive officer owned 114,725 shares in the company, valued at approximately $8,295,764.75. The trade was a 17.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Shriram Revankar sold 7,000 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $74.92, for a total transaction of $524,440.00. Following the sale, the senior vice president directly owned 70,435 shares of the company's stock, valued at approximately $5,276,990.20. This trade represents a 9.04% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 99,366 shares of company stock valued at $7,352,963. 38.39% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts recently weighed in on DLB shares. Tigress Financial boosted their target price on shares of Dolby Laboratories from $112.00 to $114.00 and gave the company a "buy" rating in a research note on Friday, August 15th. Baird R W upgraded shares of Dolby Laboratories to a "hold" rating in a report on Friday, September 5th. Barrington Research reissued an "outperform" rating and issued a $100.00 price objective on shares of Dolby Laboratories in a research report on Friday. Wall Street Zen upgraded shares of Dolby Laboratories from a "hold" rating to a "buy" rating in a research report on Saturday, August 30th. Finally, Robert W. Baird started coverage on shares of Dolby Laboratories in a research note on Friday, September 5th. They issued a "neutral" rating and a $74.00 target price for the company. Three equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Dolby Laboratories currently has a consensus rating of "Moderate Buy" and an average target price of $95.75.

Dolby Laboratories Company Profile

Dolby Laboratories, Inc creates audio and imaging technologies that transform entertainment at the cinema, DTV transmissions and devices, mobile devices, OTT video and music services, home entertainment devices, and automobiles. The company develops and licenses its audio technologies, such as AAC & HE-AAC, a digital audio codec solution used for a range of media applications; AVC, a digital video codec with high bandwidth efficiency used in various media devices; Dolby AC-4, a digital audio coding technology that delivers new audio experiences to a range of playback devices; and Dolby Atmos technology for cinema and various media devices.